These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 19150090)

  • 1. Laterality alone should not drive selection of candidates for hemi-ablative focal therapy.
    Tareen B; Godoy G; Sankin A; Temkin S; Lepor H; Taneja SS
    J Urol; 2009 Mar; 181(3):1082-9; discussion 1089-90. PubMed ID: 19150090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer?
    Tareen B; Godoy G; Sankin A; Temkin S; Lepor H; Taneja SS
    BJU Int; 2009 Jul; 104(2):195-9. PubMed ID: 19191784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Appropriate candidates for hemiablative focal therapy are infrequently encountered among men selected for radical prostatectomy in contemporary cohort.
    Tareen B; Sankin A; Godoy G; Temkin S; Lepor H; Taneja SS
    Urology; 2009 Feb; 73(2):351-4; discussion 354-5. PubMed ID: 19038430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database.
    Scales CD; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL; Freedland SJ;
    J Urol; 2007 Oct; 178(4 Pt 1):1249-52. PubMed ID: 17698131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy--can we predict adverse pathological outcomes?
    Thong AE; Shikanov S; Katz MH; Gofrit ON; Eggener S; Zagaja GP; Shalhav AL; Zorn KC
    J Urol; 2008 Dec; 180(6):2436-40. PubMed ID: 18930486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of prostate gland weight in robot assisted laparoscopic radical prostatectomy.
    Link BA; Nelson R; Josephson DY; Yoshida JS; Crocitto LE; Kawachi MH; Wilson TG
    J Urol; 2008 Sep; 180(3):928-32. PubMed ID: 18635217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Percent tumor involvement and risk of biochemical progression after radical prostatectomy.
    Rampersaud EN; Sun L; Moul JW; Madden J; Freedland SJ
    J Urol; 2008 Aug; 180(2):571-6; discussion 576. PubMed ID: 18554662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological features after radical prostatectomy in potential candidates for active monitoring.
    Griffin CR; Yu X; Loeb S; Desireddi VN; Han M; Graif T; Catalona WJ
    J Urol; 2007 Sep; 178(3 Pt 1):860-3; discussion 863. PubMed ID: 17631347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer.
    Mouraviev V; Mayes JM; Sun L; Madden JF; Moul JW; Polascik TJ
    Cancer; 2007 Aug; 110(4):906-10. PubMed ID: 17587207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens.
    Whittemore DE; Hick EJ; Carter MR; Moul JW; Miranda-Sousa AJ; Sexton WJ
    J Urol; 2008 Feb; 179(2):516-22; discussion 522. PubMed ID: 18076949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy.
    Mouraviev V; Sun L; Madden JF; Mayes JM; Moul JW; Polascik TJ
    Urology; 2007 Dec; 70(6):1141-5. PubMed ID: 18158035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system.
    van Oort IM; Witjes JA; Kok DE; Kiemeney LA; Hulsbergen-Van De Kaa CA
    BJU Int; 2008 Aug; 102(4):438-41. PubMed ID: 18336608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathological features of Gleason score 6 prostate cancers in the low and intermediate range of prostate-specific antigen level: is there a difference?
    Pelzer AE; Colleselli D; Bektic J; Steiner E; Ramoner R; Mitterberger M; Schwentner C; Schaefer G; Ongarello S; Bartsch G; Horninger W
    BJU Int; 2008 Apr; 101(7):822-5. PubMed ID: 18261154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological stage T2 subgroups to predict biochemical recurrence after prostatectomy.
    Kordan Y; Chang SS; Salem S; Cookson MS; Clark PE; Davis R; Herrell SD; Baumgartner R; Phillips S; Smith JA; Barocas DA
    J Urol; 2009 Nov; 182(5):2291-5. PubMed ID: 19758638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy.
    Polascik TJ; Mayes JM; Sun L; Madden JF; Moul JW; Mouraviev V
    Prostate; 2008 Sep; 68(13):1380-6. PubMed ID: 18543281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3-year actuarial biochemical recurrence-free survival following laparoscopic radical prostatectomy: experience from a tertiary referral center in the United States.
    Pavlovich CP; Trock BJ; Sulman A; Wagner AA; Mettee LZ; Su LM
    J Urol; 2008 Mar; 179(3):917-21; discussion 921-2. PubMed ID: 18207191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy.
    Polascik TJ; Mayes JM; Schroeck FR; Sun L; Madden JF; Moul JW; Mouraviev V
    Cancer; 2009 May; 115(10):2104-10. PubMed ID: 19288576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.
    Sun L; Caire AA; Robertson CN; George DJ; Polascik TJ; Maloney KE; Walther PJ; Stackhouse DA; Lack BD; Albala DM; Moul JW
    J Urol; 2009 Nov; 182(5):2242-8. PubMed ID: 19758616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Final outcomes of patients with low-risk prostate cancer suitable for active surveillance but treated surgically.
    Louie-Johnsun M; Neill M; Treurnicht K; Jarmulowicz M; Eden C
    BJU Int; 2009 Nov; 104(10):1501-4. PubMed ID: 19426187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes for men younger than 50 years undergoing radical prostatectomy.
    Twiss C; Slova D; Lepor H
    Urology; 2005 Jul; 66(1):141-6. PubMed ID: 15992906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.